<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND AND PURPOSE: We have previously demonstrated that pretreatment with selective kappa-opioid <z:chebi fb="4" ids="48705">agonist</z:chebi> BRL 52537 hydrochloride [(+/-)-1-(3,4-dichlorophenyl) <z:chebi fb="9" ids="46887">acetyl</z:chebi>-2-(1-pyrrolidinyl) methylpiperidine], provides ischemic neuroprotection following transient focal <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> in rats </plain></SENT>
<SENT sid="1" pm="."><plain>The present study was undertaken to a) define "therapeutic opportunity" for ischemic neuroprotection with BRL 52537, and b) determine if BRL 52537 attenuates <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>-evoked efflux of <z:chebi fb="40" ids="18243">dopamine</z:chebi> and its metabolites in the striatum in vivo following transient focal <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: Using the intraluminal filament technique, <z:chebi fb="2" ids="5615">halothane</z:chebi>-anesthetized male Wistar rats were subjected to 2 hours of middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> (MCAO) </plain></SENT>
<SENT sid="3" pm="."><plain>In a blinded, randomized fashion, rats were treated with saline (vehicle) or 1 mg/Kg/hr BRL 52537 infusion for 22 hours, initiated at <z:hpo ids='HP_0003674'>onset</z:hpo>, 2, 4, or 6 hours of reperfusion (Rep) </plain></SENT>
<SENT sid="4" pm="."><plain>In a separate set of experiments utilizing in vivo microdialysis, extracellular levels of <z:chebi fb="40" ids="18243">dopamine</z:chebi> and its metabolites were determined in the striatum during 2 hours of MCAO and 3 hours of reperfusion </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: <z:mpath ids='MPATH_124'>Infarct</z:mpath> volume (% of contralateral structure; mean +/-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">SEM</z:e>) in cortex was significantly attenuated when BRL 52537 was administered at reperfusion (22+/-6%), 2 hours (21+/-6%), and 4 hours (18+/-5%) compared with controls (39+/-5%) </plain></SENT>
<SENT sid="6" pm="."><plain>In striatum, <z:mpath ids='MPATH_124'>infarct</z:mpath> volume was significantly attenuated when BRL 52537 was administered at reperfusion (38+/-9%), 2 hours (40+/-8%), 4 hours (50+/-8%), and 6 hours (46+/-9%) as compared with controls (70+/-4%) </plain></SENT>
<SENT sid="7" pm="."><plain>A 6- to 8-fold increase in <z:chebi fb="40" ids="18243">dopamine</z:chebi> in microdialysates occurred within 40 minutes of MCAO </plain></SENT>
<SENT sid="8" pm="."><plain>Pretreatment with BRL 52537 did not alter microdialysate levels of <z:chebi fb="40" ids="18243">dopamine</z:chebi> or its metabolites in the striatum during MCAO and early reperfusion, as compared with saline controls </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSIONS: These data demonstrate that BRL 52537 provides robust ischemic neurprotection with a long therapeutic opportunity (at least 6 hours) without altering <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>-evoked efflux of <z:chebi fb="40" ids="18243">dopamine</z:chebi> (<z:mp ids='MP_0000273'>DA</z:mp>) and its metabolites in striatum during <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> and early reperfusion </plain></SENT>
</text></document>